Cerus Corporation Reports Record Revenue and Narrowing Losses in 2025
Event summary
- Cerus Corporation reported full-year 2025 revenue of $233.8 million, up 16% year-over-year, with product revenue reaching a record $206.1 million.
- Net loss narrowed to $15.6 million for the year, compared to $20.9 million in 2024, with positive non-GAAP adjusted EBITDA for the second consecutive year.
- INTERCEPT Fibrinogen Complex (IFC) demand more than doubled, with full-year revenue increasing approximately 80% to $16.7 million.
- Entered into a group purchasing agreement with Blood Centers of America (BCA), covering its licensed product portfolio.
The big picture
Cerus Corporation's strong 2025 financial results reflect its disciplined execution in safeguarding the global blood supply. The company's record kit shipments and narrowing net loss underscore its strategic focus on expanding access to INTERCEPT technologies. The partnership with Blood Centers of America (BCA) further solidifies its position in the U.S. blood supply market, while ongoing product development programs aim to drive future growth.
What we're watching
- Revenue Growth Trajectory
- Whether Cerus can sustain its 9% to 11% product revenue growth guidance for 2026 amid macroeconomic challenges.
- Product Innovation
- The pace at which Cerus advances its red blood cell and INT200 programs, given increased development costs.
- Operational Efficiency
- How Cerus manages inflationary pressures and foreign exchange rates to maintain product gross margins.
Related topics